2006
DOI: 10.1203/01.pdr.0000246802.57692.ea
|View full text |Cite
|
Sign up to set email alerts
|

Congenital Disorders of N-Glycosylation Including Diseases Associated With O- as Well as N-Glycosylation Defects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
47
0
3

Year Published

2007
2007
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 69 publications
(50 citation statements)
references
References 97 publications
(122 reference statements)
0
47
0
3
Order By: Relevance
“…In plants and animals, some genes involved in the dolicholrelated N-linked glycosylation pathway have been identified, and defects in the human genes lead to serious diseases called congenital disorders of glycosylation (Koiwa et al, 2003;Kranz et al, 2004Kranz et al, , 2007Leroy, 2006). In this study, we found that the lew1 mutation reduced protein glycosylation levels and identified two specific proteins with altered glycosylation.…”
Section: Discussionmentioning
confidence: 65%
“…In plants and animals, some genes involved in the dolicholrelated N-linked glycosylation pathway have been identified, and defects in the human genes lead to serious diseases called congenital disorders of glycosylation (Koiwa et al, 2003;Kranz et al, 2004Kranz et al, , 2007Leroy, 2006). In this study, we found that the lew1 mutation reduced protein glycosylation levels and identified two specific proteins with altered glycosylation.…”
Section: Discussionmentioning
confidence: 65%
“…CDGs are autosomal dominant disorders in which afflicted individuals present with severe developmental delay (53)(54)(55)(56)(57). CDGs are caused by mutant or missing glycogenes, primarily glycosyltransferases, resulting in glycoproteins with relatively modest reductions in the levels and types of attached sugars.…”
Section: Sialylated O-glycans Modulate K V 21 K V 42 and K V 43 mentioning
confidence: 99%
“…To date, 30 CDG hypoglycosylation defects have been identified, including 17 N-glycosylation defects (13 CDG-I or N-glycan assembly defects and 4 CDG-II or N-glycan processing defects), 6 O-glycosylation defects, 5 combined N-and Oglycosylation defects, and 2 lipid glycosylation defects (2)(3)(4)(5)(6)(7)(8)(9).…”
Section: © 2007 American Association For Clinical Chemistrymentioning
confidence: 99%